trial · primary record
Miltenyi CD34 Reagent System
Severe Aplastic Anemia
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 120 |
| Primary completion | 2028-06-30 |
| Primary endpoint | Primary endpoint of this study is chronic GVHD by one year. |
| Registry ID | NCT01174108 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:33:04.122Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT01174108
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.